INSTIL BIO INC

TILNASDAQ

🏆 #3593 by market capEarnings Aug 12US Equity

$7.49▲ $0.08 (+1.08%)

Market closed · at close

1h—

24h▲ 1.1%

7d▼ 0.1%

14d▲ 5.2%

30d▼ 3.7%

1y▼ 73.3%

🏦Market Cap

$51M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $7.42 – $7.53
52-Week Range: $5.67 – $33.83
Volume: $2.52B
Avg Volume: $2.74B
Shares Outstanding: 6.8M
Next Earnings: Oct 15, 2026

Fundamentals Snapshot

Annual Revenue: $5M
Last Q Revenue: $1M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-7.08
Dividend Yield: —

Why Investors Own TIL

✓High-growth profile — revenue up +43.8% YoY with expanding US Equity exposure.
✓Healthy economics — 62% gross margin and 15% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$5M▲ +45.5% YoY

Gross Margin (TTM)

62.3%▲ +0.7% YoY

Operating Income (TTM)

$1M▲ +45.5% YoY

Free Cash Flow (TTM)

$731,861▲ +45.5% YoY

About INSTIL BIO INC

Instil Bio, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on devising novel therapeutic options for individuals battling cancer. A cornerstone of their research involves the advancement of autologous tumor-infiltrating lymphocyte (TIL) cell therapies. Their developmental portfolio features ITIL-168, currently under investigation for a range of malignancies including melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer. Another promising candidate, ITIL-306, is engineered to identify folate receptor alpha (FOLR1) and is being explored for gynecological cancers, non-small cell lung cancer, renal cancer, and other conditions. This company was founded in 2018 and has its principal office situated in Dallas, Texas.

🦦